The DOI matches its Crossref record; 162 of the 165 references it cites were found in a registry or an index; 194 of the 302 sources its claims cite were checked for support.
Epidemiology of Invasive Candidiasis
Open accessAbstract
Invasive candidiasis (IC) is an increasingly prevalent, costly, and potentially fatal infection brought on by the opportunistic yeast, Candida . Previously, IC has predominantly been caused by C. albicans which is often drug susceptible. There has been a global trend towards decreasing rates of infection secondary to C. albicans and a rise in non- albicans species with a corresponding increase in drug resistance creating treatment challenges. With advances in management of malignancies, there has also been an increase in the population at risk from IC along with a corresponding increase in incidence of breakthrough IC infections. Additionally, the emergence of C. auris creates many challenges in management and prevention due to drug resistance and the organism’s ability to transmit rapidly in the healthcare setting. While the development of novel antifungals is encouraging for future management, understanding the changing epidemiology of IC is a vital step in future management and prevention. Keywords: Candida, epidemiology, resistance, emerging, non- albicans Candida species
Overview
CoChat Summary
TL;DR
Invasive candidiasis remains a costly, morbid, and often fatal infection, with declining *C. albicans* proportions, rising non-albicans species, antifungal resistance, breakthrough infections, and the emergence of multidrug-resistant *C. auris*. This review synthesizes global epidemiology, diagnostics, burden, species distribution, resistance trends, management, and prevention.
Key findings
- Candidemia causes an estimated 22,000 infections annually in the United States and is the second most common healthcare-associated bloodstream infection nationally; all-cause in-hospital mortality has been reported as high as 36% in the US, 38–42% at 30 days in Europe, ~40% in Asia, 33–60% in MENA, and 30–70% in South America.
- The proportion of *C. albicans* has fallen from 70–80% in the 1980–1990s to 40–60% in most areas; in ECMM studies, *C. albicans* decreased from 56.4% (1997–1999) to 54% (2006–2008) to 46.0% (2018), while *C. glabrata* rose from 13.9% to 21.0%.
- Resistance is increasing: CDC surveys report *C. glabrata* fluconazole resistance of 7–11% and echinocandin resistance of 2–8%; *C. parapsilosis* fluconazole resistance exceeds 50% in some series and is 4–10% in the US; *C. auris* shows fluconazole resistance in 70–90% of isolates, echinocandin resistance up to 7%, amphotericin B resistance up to 35%, and pan-resistance most commonly in India/South Asia (3%).
- Breakthrough *Candida* infections occur in fewer than 10% of at-risk patients but can constitute up to 40% of all *Candida* infections in selected series; 30-day mortality is similar to de novo infections (~30%). Blood cultures have only ~50% sensitivity for invasive candidiasis; T2Candida has 91% sensitivity and 94% specificity, while 1,3-β-D-glucan sensitivity averages ~85% but specificity is often below 60%.
Methods
- Narrative review of invasive candidiasis epidemiology, diagnostics, burden, geographic species differences, emerging species, breakthrough infections, antifungal susceptibility, management, antifungal pipeline, and infection control.
- Evidence is drawn from published literature, including population-based surveillance, meta-analyses, multicenter ECMM/SENTRY/CDC/TRANSNET studies, clinical trials, and guidelines; no new primary data are presented.
- Main analysis is qualitative synthesis; no systematic review search strategy, risk-of-bias assessment, or quantitative pooling is described.
Limitations
- Stated: current diagnostics have limited sensitivity/specificity that affect epidemiologic assessment; intra-abdominal candidiasis lacks standardized definitions; there are no population-based data sources for Asia, the Middle East, Africa, or Latin America; most IC studies are single-center or smaller multicenter analyses; candidemia is generally not reportable, so reporting is voluntary; lack of standardized methodologies and denominators limits comparisons.
- Stated: the overall burden of IC is likely underestimated because of global surveillance gaps and diagnostic performance limitations.
- Evident: as a narrative review, it does not provide a systematic search, formal quality appraisal, or quantitative synthesis, so conclusions may inherit publication and surveillance biases from the cited literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
104 Valid · 10 Not valid · 40 Not checked · 16 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Resistance to all three classes of antifungals is reported most commonly in India in South Asia (3%), whereas this is much less common in other regions of the world.122–124”
§ Epidemiology of Invasive Candidiasis > Trends and Antifungal Susceptibility of Candida Species
What the sources say
- Partly supportedcites [122] Lockhart, 2017, Clin Infect Dis sourceExperimental — accuracy not yet measured
The Results (Antifungal Susceptibility Testing; page unavailable) report that the two isolates resistant to all three major antifungal classes were both from India, supporting the geographic comparison within this study’s sample. The paper reports 4% of all tested isolates—not 3% of Indian isolates—and its samples from four countries do not establish how common this resistance is worldwide. (LLM, conf=0.88)
- Partly supportedcites [123] Chowdhary, 2017, PLoS Pathog sourceExperimental — accuracy not yet measured
In “Is antifungal resistance in C. auris a therapeutic challenge?” (page unavailable), the paper reports that a low number (4%) of isolates resist all antifungal classes. It does not give the claimed 3% figure for India or establish that resistance to all three classes is less common elsewhere. (LLM, conf=0.84)
- Disputedcites [124] Chowdhary, 2018, J Antimicrob Chemother sourceExperimental — accuracy not yet measured
The JAC section reports that 2% of the Indian isolates had combined azole and echinocandin resistance. Resistance to all three classes could not therefore occur in 3% of those isolates. The Discussion’s 3% figure refers to echinocandin resistance alone among US isolates, and the paper does not establish that triple-class resistance is most common in India. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Historically this organism has been pan-susceptible to triazoles, echinocandins, and amphotericin B.”
§ Epidemiology of Invasive Candidiasis > Trends and Antifungal Susceptibility of Candida Species
What the sources say
- Disputedcites [62] Pfaller, 2019, Open Forum Infect Dis sourceExperimental — accuracy not yet measured
The Results sections report fluconazole resistance in C. tropicalis isolates, including 9.2% in the Asia-Pacific region, and echinocandin resistance of 0.5%–0.7% during the surveillance period. That contradicts pan-susceptibility across those drug classes. The Methods list the agents tested and do not include amphotericin B, so the paper does not establish that part of the claim. The supplied copy gives section labels but no page numbers. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In the US, fluconazole resistance rates range between 4–10%; rates are much higher in other parts of the world including Japan, Western Europe, and Latin America.”
§ Epidemiology of Invasive Candidiasis > Trends and Antifungal Susceptibility of Candida Species
What the sources say
- Disputedcites [62] Pfaller, 2019, Open Forum Infect Dis sourceExperimental — accuracy not yet measured
Table 4 (Results, Fluconazole Resistance by Geographic Area and Species) reports 3.7% fluconazole resistance for North American C. parapsilosis isolates in 2006–2016, rather than a US rate of 4–10%. It reports 4.6% in Europe and 4.3% in Latin America—only slightly above the North American rate, not much higher. The table does not give a separate rate for Japan. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
- Could not verifycites [103] Adam, 2021, Open Forum Infect Dis sourceExperimental — accuracy not yet measured
The Antifungal Susceptibility Testing section reports 4%–7% fluconazole nonsusceptibility in C. parapsilosis isolates from Switzerland, not resistance rates in the US. A search for US C. parapsilosis fluconazole resistance rates found no passage giving the claimed 4%–10% range. (LLM, conf=0.76)
- Partly supportedcites [112] Arastehfar, 2020, J Fungi sourceExperimental — accuracy not yet measured
Section 6.3 reports fluconazole-resistant C. parapsilosis, and section 9 says it has been observed in the USA. Neither passage gives a US resistance rate of 4–10%; the percentages in section 6.3 refer to other regions. (LLM, conf=0.83)
- Could not verifycites [120] Pfaller, 2011, J Clin Microbiol sourceExperimental — accuracy not yet measured
The Results and Discussion passages report susceptibility of Aspergillus species to itraconazole, posaconazole, and voriconazole; page numbers are unavailable in our copy. Searches for fluconazole, C. parapsilosis, and the stated geographic comparison found no passage reporting the claimed US resistance rate. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In the US, fluconazole resistance rates range between 4–10%; rates are much higher in other parts of the world including Japan, Western Europe, and Latin America.”
§ Epidemiology of Invasive Candidiasis > Trends and Antifungal Susceptibility of Candida Species
What the sources say
- Disputedcites [62] Pfaller, 2019, Open Forum Infect Dis sourceExperimental — accuracy not yet measured
The Results (Table 4; page not provided) report C. parapsilosis fluconazole resistance of 3.7% in North America, 4.6% in Europe, 4.3% in Latin America, and 0.6% in Asia-Pacific. Europe and Latin America are only slightly higher than North America, while Asia-Pacific is lower—not the much higher rates claimed. The table does not give separate rates for the US, Japan, or Western Europe. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [103] Adam, 2021, Open Forum Infect Dis sourceExperimental — accuracy not yet measured
The Discussion says several countries have reported emerging azole resistance in C. parapsilosis. However, it does not identify Japan, Western Europe, or Latin America or compare their fluconazole resistance rates with those in the US. The susceptibility-testing section reports Swiss nonsusceptibility rates of 6%, 7%, and 4% across the study periods, not the claimed international comparison. (LLM, conf=0.76)
- Disputedcites [112] Arastehfar, 2020, J Fungi sourceExperimental — accuracy not yet measured
Section 6.3 (page unavailable) reports 4.6% fluconazole-resistant C. parapsilosis isolates in Latin America—not a rate much higher than the citing sentence’s stated US range of 4–10%. The section does not provide the claimed US rate or comparable rates for Japan and Western Europe. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
- Could not verifycites [120] Pfaller, 2011, J Clin Microbiol sourceExperimental — accuracy not yet measured
The Results and Discussion passages report susceptibility of Aspergillus species to itraconazole, posaconazole, and voriconazole; no page numbers are provided. Searches for C. parapsilosis, fluconazole, and the claimed regional resistance rates found no passage addressing that comparison. (LLM, conf=0.78)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Ibrexafungerp is currently only FDA approved as oral therapy for vulvovaginal candidiasis, although clinical trials for invasive candidiasis step-down therapy, refractory candidiasis, and C. auris are ongoing.149,156–159”
§ Epidemiology of Invasive Candidiasis > The Antifungal Pipeline for IC
What the sources say
- Partly supportedcites [149] Seiler, 2021, Curr Fungal Infect Rep sourceExperimental — accuracy not yet measured
The Ibrexafungerp section (Agents in Phase III Clinical Trials; page unavailable) describes oral ibrexafungerp in ongoing trials, and the References list a phase III study for vulvovaginal candidiasis. Our copy does not state that ibrexafungerp is FDA approved, or that vulvovaginal candidiasis is its only approved indication. (LLM, conf=0.83)
- Supportedcites [156] Hoenigl, 2021, Drugs source
The Ibrexafungerp section states that the FDA approved ibrexafungerp for oral use in patients with vulvovaginal candidiasis. Its Future Role subsection says other approvals were still expected, supporting the claim that this was its only FDA-approved use at the time covered by the paper. (LLM, conf=0.92)
- Supportedcites [157] Mccarthy, 2022, Drugs R D source
The Abstract states that the FDA approved ibrexafungerp for vulvovaginal candidiasis following trials of oral treatment. The Introduction identifies it as an oral formulation, while Future Directions treats other indications as under investigation rather than approved. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [158] Spec, 2019, J Antimicrob Chemother source
- Disputedcites [159] Jallow, 2021, J Fungi sourceExperimental — accuracy not yet measured
Section 8, “Indications and Usage,” says the FDA had accepted a new drug application for oral ibrexafungerp to treat vulvovaginal candidiasis; it does not say the drug was approved. Section 9, “Conclusions,” says an FDA action date was still pending and a US commercial launch was planned, contrary to the claim that approval had already been granted. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
90 more claims · 59 with their cited sources checked
Create a free account to see all 170 claims and to verify the 4 references still open.
- Probably not a substantial claim. 25
- It may state two separate claims as one. 58
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Epidemiology of Invasive Candidiasis > Geographic Differences of Invasive Candidiasis
“to 2018 (21.4%)56”
§ Epidemiology of Invasive Candidiasis > Geographic Differences of Invasive Candidiasis
“| C. glabrata | 13.9% | 13.8% | 21.0% |”
Citations
Cites
Guidelines for the Prevention of Intravascular Catheter-related Infections
O'Grady, N. P., Alexander, M., Burns, L. A., Dellinger, E. P., Garland, J., Heard, S. O., Lipsett, P. A., Masur, H., Mermel, L. A., Pearson, M. L., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir257 · Cited by 4,699
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200 · cited 6×
“125,164 C. auris outbreaks in healthcare facilities has recently seen an increase, greatly facilitated by the COVID pandemic with the large numbers of critically ill, mechanically ventilated patients and likely breaches in infection control practices.”
BackgroundInfluentialSelf-citationEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“33 More recent data using US electronic medical records showed there was no significant change in the incidence between 2009–2017, with an overall incidence of inpatient IC of 90 per 100,000 hospitalizations.”
MethodDonnelly, J. P., Chen, S. C., Kauffman, C. A., Steinbach, W. J., Baddley, J. W., Verweij, P. E., Clancy, C. J., Wingard, J. R., Lockhart, S. R., Groll, A. H., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1008 · Cited by 2,917
Self-citationLockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662
Self-citationGlobal incidence and mortality of severe fungal disease
Denning, D. W. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00692-8 · Cited by 1,640
Pappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., & Kullberg, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.26 · Cited by 1,636 · cited 8×
“18,62,66 However, fluconazole resistance has emerged over the last decade and over 50% of C. parapsilosis isolates are resistant in some series.”
BackgroundMethodInfluentialSelf-citationComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Kullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“92 Less common species such as C. lusitaniae and C. guilliermondii have also been reported.”
BackgroundMorrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Research works printed but not linked: 2
- Ulrych, 2020, Epidemiol Mikrobiol Imunol, 69, 57
- 2020, Clinical Practice of Medical Mycology in Asia
Cited by
Candida auris: Epidemiology Update and a Review of Strategies to Prevent Spread
Hayes, J. F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226675 · Cited by 45
Biofilm Formation as a Pathogenicity Factor of Medically Important Fungi
Vila, T. V. M., & Rozental, S. (2016) · InTech eBooks · doi:10.5772/62768 · Cited by 30
Growth defects resulting from inhibiting ERG20 and RAM2 in Candida glabrata
Nakayama, H., Ueno, K., Uno, J., Nagi, M., Tanabe, K., Aoyama, T., Chibana, H., & Bard, M. (2010) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2010.02205.x · Cited by 22
Invasive candidiasis in intensive care medicine: shaping the future of diagnosis and therapy
Martín‐Loeches, I., Cornely, O. A., Denning, D. W., Guinea, J., Bassetti, M., Maertens, J. A., Hoenigl, M., Kanj, S. S., Slavin, M. A., Ostrosky-Zeichner, L. L., et al. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-08151-1 · Cited by 23
Self-citationThe impact of phenotypic heterogeneity on fungal pathogenicity and drug resistance
Kozubowski, L., & Berman, J. G. (2025) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaf001 · Cited by 14
Metadata
- Authors
- Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G.
- Affiliations
- University of California Davis Medical Center (US)
- Centers for Disease Control and Prevention (US)
- The University of Texas Health Science Center at Houston (US)
- Medical University of Graz (AT)
- University of Alabama at Birmingham (US)
- Corresponding author
- Bays, Derek
- ORCID
- Venue
- Clinical Epidemiology
- Publisher
- Informa UK Limited
- Published
- 2024-08
- Volume
- Volume 16
- Pages
- 549-566
- ISSN
- 1179-1349 (ISSN-L)
- PMC
- PMC11366240
- OpenAlex
- W4401967436
- Cited by
- 109
- References
- 165
- Citations by year
- 2026: 62 · 2025: 42 · 2024: 2
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Epidemiology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- National Institutes of Health (UL1TR001860, KL2TR001859)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- invasive candidiasis, Candida albicans, non-albicans Candida, Candida auris, antifungal resistance, opportunistic fungal infection, emerging fungal pathogens, antifungal agents, nosocomial transmission, cancer patients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
